RxDoctor Payments Data

Christopher Eckstein, MD

Neurology · Durham, NCNPI 1003023201

Payments from drug & device makers

What this record shows

10 manufacturers reported payments, led by AstraZeneca at 35.2% of the total. Reporting peaked in 2021 at $2,236 and has fallen 66.4% since, to $752 in 2025.

$5,958in general payments, 2019–2025

Across 45 payments — averaging $132.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • TG Therapeutics, Inc.$1K
  • Biogen$874
  • EMD Serono, Inc.$672
  • Amgen$509
  • Bristol Myers Squibb$135
  • plus $353 from 4 others
$223,437in research payments, 2019–2025

Across 55 payments — averaging $4062.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$147K
  • Biogen$55K
  • Novartis$20K
  • Sanofi US Services Inc.$750

What the payments were for

  • Consulting fees$3,00050%
  • Food & beverage$2,95850%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,958 in reported general payments places this provider in the 70th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$33,430
Medicare patients
227
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab30$318,759
AubagioTeriflunomide15$133,182
Avonex (4 Pack)Interferon Beta-1a13$124,622
VumerityDiroximel Fumarate12$105,668
Glatiramer Acetate13$19,973
Dalfampridine ErDalfampridine41$16,835
Teriflunomide21$12,103
Pregabalin79$2,279
Gabapentin117$1,732
Mycophenolate Mofetil18$1,492
Lacosamide22$1,401
Oxcarbazepine47$1,297
Baclofen75$1,137
Modafinil33$717
Levetiracetam18$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack), Vumerity$874$230,29025 claims
SanofiAubagio$103$133,18215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 566 neurology providers in North Carolina.

Other neurology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →